Jun 28, 2023 / 12:00PM GMT
Oliver Maier - Bayer Aktiengesellschaft - Head of IR
It's a great pleasure to welcoming you here at Bayer's Research and Innovation Center here in Cambridge. This is a hub that we've inaugurated about a year ago. We have so much in store for you today, and we are really excited to share that with you with an update on our key pillars of our R&D strategy, and -- which we think is a step change in innovation are characterized, including investments in our leading technology platforms in cell and gene therapies and proteomics. We have significantly expanded our R&D capabilities and our presence in the world's leading innovation hubs.
I know everybody might have lots of different questions, but still, I think we should focus on the R&D and innovation side of things today. This is such a unique opportunity to have all these great minds in one room, and we should make use of that and stay focused. So let's have a short look at the agenda today.
You see that we will have live presentations from 7 speakers as well as several Q&A sessions, 2 short ones and a longer one at the end.
Bayer AG Pharmaceuticals R&D Event Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot